Phar­ma-backed Min­er­vaX rais­es €54M as it aims to move its group B Strep­to­coc­cus vac­cine in­to PhI­II

Near­ly a year af­ter rais­ing its largest fi­nanc­ing so far, the Dan­ish biotech Min­er­vaX is back with an up­sized fi­nanc­ing round of €54 mil­lion ($57.3 mil­lion) to fund late-stage work for its vac­cine against group B Strep­to­coc­cus, the com­pa­ny an­nounced Wednes­day.

Group B Strep­to­coc­cus is a bac­te­ria re­spon­si­ble for near­ly 50% of all life-threat­en­ing in­fec­tions in new­borns. It can al­so lead to oth­er prob­lems in preg­nan­cy, like still­births, ac­cord­ing to Min­er­vaX.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER